Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2−/− mouse model of sclerosing cholangitis via immunomodulatory effects
Claudia Fuchs(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Hubert Scharnagl(Medical University of Graz), Annika Wahlström(University of Gothenburg), Christoph J. Binder(Medical University of Vienna), Veronika Mlitz(Medical University of Vienna), Hanns–Ulrich Marschall(University of Padua), Tim Hendrikx(Medical University of Vienna), Tatjana Stojaković, Marcus Ståhlman(University of Gothenburg), Emmanuel D. Dixon(Medical University of Vienna)
Cited by 16
Related Papers
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
|Nature Medicine|2017|1.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2020|1.5k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k